Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Tarsus Pharmaceuticals, Inc

Contributing Author

Recent Articles by Tarsus Pharmaceuticals, Inc

Sep-01
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Aug-06
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth TARS +6.59% GlobeNewswire
Aug-06
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing TARS +6.59% GlobeNewswire
Aug-06
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position TARS +6.59% GlobeNewswire
Aug-05
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 TARS +6.59% GlobeNewswire
Jul-13
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth TARS TARS -5.40% GlobeNewswire
Jul-08
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 TARS TARS -5.30% GlobeNewswire
May-28
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
May-14
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans TARS GlobeNewswire
May-07
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Apr-29
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 TARS GlobeNewswire
Mar-31
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease TARS GlobeNewswire
Mar-23
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus TARS GlobeNewswire
Feb-26
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Feb-23
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements TARS TARS +7.79% GlobeNewswire
Feb-18
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors TARS GlobeNewswire
Feb-17
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 TARS GlobeNewswire
Nov-24
Tarsus to Participate in Upcoming Investor Conference TARS GlobeNewswire
Nov-05
Tarsus to Participate in Upcoming Investor Conference TARS GlobeNewswire
Nov-04
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements TARS GlobeNewswire
Oct-28
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 TARS GlobeNewswire
Aug-27
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Aug-06
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements TARS TARS +15.15% GlobeNewswire
Jul-30
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 TARS GlobeNewswire
May-29
Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
May-08
Tarsus to Participate in Upcoming Investor Conferences TARS TARS -5.05% GlobeNewswire
May-01
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements TARS TARS -5.84% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)